DOCSLIB.ORG

Inactivated Polio Vaccine (IPV) Frequently Asked Questions March 2014

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inactivated Polio Vaccine (IPV) Frequently Asked Questions March 2014 Inactivated Polio Vaccine (IPV) Frequently Asked Questions March 2014 1. When did GAVI start supporting inactivated polio vaccine (IPV)? In November 2013, the GAVI Board decided to open a funding window such that the GAVI Alliance can invite GAVI-eligible and GAVI-graduating countries to submit proposals for support to introduce one dose of inactivated polio vaccine (IPV) into their routine immunisation programmes by the end of 2015, in line with the Polio Eradication and Endgame Strategic Plan (Endgame Plan) 2013-2018. The Endgame Plan was developed following the May 2012 declaration by the World Health Assembly of the completion of poliovirus eradication to be a programmatic emergency for global public health and called for an endgame strategy. The plan outlines a comprehensive approach for completing eradication, including strategic objective 2, which calls for the introduction of IPV in all OPV-only using countries by the end of 2015. The primary role of IPV will be to maintain immunity against type 2 poliovirus, while withdrawing type 2 containing OPV globally. A key component of this objective is the strengthening of routine immunisation systems, as high immunisation coverage is essential to achieving the goals of the polio endgame and long-term sustainability of polio eradication efforts. Recognising the Global Polio Eradication Initiative’s (GPEI) responsibility for eradicating polio, GAVI’s overall objective related to polio eradication is to improve immunisation services in accordance with GAVI’s mission and goals while supporting eradication by harnessing the complementary strengths of GAVI and GPEI in support of countries. More information on the Endgame Plan and GPEI can be found here. Countries can consult the application information and resources available on the GAVI website at: http://www.gavialliance.org/support/apply/. 2. Is our country eligible to apply for GAVI support for IPV? GAVI-eligible and GAVI-graduating countries are eligible for IPV support. 1 Please see Annex A for the full list of countries eligible to apply for IPV through GAVI. There is no requirement for a minimum national DTP3 coverage level prior to application. Countries currently eligible for GAVI support that cross the eligibility threshold while the IPV application window is still open will continue to be eligible for IPV support.2 1 Note: Support for IPV introduction in India would be considered separately by the GAVI Board and therefore not in the scope of these guidelines. Ukraine has already introduced IPV. 2 The policy exceptions will be reconsidered by the GAVI Board in 2018. 1 3. What kind of GAVI support can a country receive to introduce IPV? Countries can receive GAVI support to introduce IPV in the following ways: Vaccine and supplies: GAVI-eligible and GAVI-graduating countries may receive IPV support based on a one-dose vaccination schedule, as well as associated supplies (auto-disable syringes and waste disposal boxes). Vaccine introduction grant (VIG): Countries approved for IPV introduction will also receive a one-time cash grant to support a share of the additional costs related to the new vaccine introduction, with any remainder necessary, being funded by the government or partners. Technical Assistance (TA): Countries can request assistance with planning for IPV implementation through WHO and UNICEF. Co-financing: GAVI has made a policy exception for IPV to its usual co-financing requirement due to the unique needs of polio eradication. Therefore, countries are not required to co-finance IPV. Countries are encouraged to contribute to vaccine and/or supply costs if they are able to. If a country is in default on the co-financing requirement for other vaccines, it is still eligible to apply for IPV.3 4. What is the application process for IPV support? When applying for IPV, the IPV application guidelines should be reviewed and the following documents must be submitted: IPV Introduction Plan (Guidance provided in Annex A and WHO’s new vaccine introduction plan template4) IPV Application Form (Annex B) IPV Introduction timeline of activities (Annex C) VIG and Operational Cost Detail Template (Annex D) All application materials can be found on GAVI’s website at: http://www.gavialliance.org/support/apply/ The completed application must be submitted electronically to the GAVI Secretariat at: [email protected]. Please see Section 2 of the IPV Support Guidelines (p. 8) for a complete checklist of mandatory items to be submitted with the application. 3 These policy exceptions will be reconsidered by the GAVI Board in 2018. 4 Further information available at: http://www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/ 2 The following table details the application submission timelines for 2014 for IPV introduction. Vaccine Introduction Application due date IRC meeting date Decision letter Grant disbursed 6 February 27 February – 7 March 30 March 28 – 30 April Within four weeks Within six weeks of of end of IRC issuing the decision 1 May 23 June – 4 July letter 15 September 10 – 21 November 5. Which IPV presentations will be available with GAVI support? Two different product presentations are available through UNICEF with GAVI support for countries planning to introduce in 2014: Single-dose vial of IPV: A single dose vial of IPV is available from July in limited quantities until 2016 when supply could increase. Ten-dose vial of IPV: The majority of available supply in this and coming years will be in a 10 dose vial presentation. A five- dose vial presentation is also expected to become WHO prequalified and available for supply towards the end of Q3/early Q4 2014 but quantities will be less than the 10 dose vial. From 2016 the supply of the five-dose vial will increase considerably with the ability to meet demand from all countries, should the need arise.i While countries should indicate their first preferred product presentation, countries should also include a second and a third preferred presentation in their application to GAVI in order to facilitate early introduction in all countries. Countries will be allowed to switch when their preferred product presentation becomes available in sufficient quantity. For information on the current IPV supply and recent tender results, please visit: http://www.unicef.org/supply/index_66260.html For information on the IPV prices and suppliers, please visit: http://www.unicef.org/supply/files/IPV.pdf For information on the single-dose vial of IPV, please visit: http://www.who.int/immunization_standards/vaccine_quality/pq_231_ipv_1dose_nvi/en/ For information on the ten-dose vial of IPV, please visit: http://www.who.int/immunization_standards/vaccine_quality/PQ_99_ipv_10_dose_sanofi_pasteur/en/ For information on the vaccines procured by UNICEF with GAVI funding, please visit: http://www.unicef.org/supply/files/Product_Menu_March_2014.pdf 3 6. Can a country applying to GAVI choose an IPV containing hexavalent vaccine (pentavalent and IPV) rather than standalone IPV? GAVI only purchases WHO prequalified vaccines and currently, there are no prequalified combination vaccines that contain IPV. The current IPV-containing combination vaccines contain an acellular pertussis component, and are available in tetravalent, pentavalent, or hexavalent formulations. These vaccines have a high price compared to the pentavalent vaccine which GAVI supports, which contains whole-cell rather than acellular pertussis. The IPV-containing combination vaccines are currently in constrained supply at the global level. An IPV-containing combination vaccine containing whole cell pertussis, which could be more affordable, is not expected before 2020.ii 7. How would GAVI support for IPV work for countries wishing to introduce more than one dose in their routine schedule? GAVI-eligible and GAVI-graduating countries may receive IPV support based on a one dose vaccination schedule, as well as associated supplies (auto-disable syringes and waste disposal boxes). GAVI’s support for a one-dose vaccination schedule follows the November 2012 WHO Strategic Advisory Group of Experts (SAGE) on immunisation recommendation that countries add at least one dose of IPV into their routine immunisation schedules.iii If a country chooses to introduce IPV with a multiple-dose schedule, the country would need to self-fund the additional doses and associated supplies. 8. Can IPV be introduced at the same time as another vaccine? Countries are encouraged to find synergy for IPV introduction with existing plans for other new vaccine introductions scheduled in 2014 or 2015. Studies conducted in Tanzania and Ghana regarding dual vaccine introductions have indicated efficiencies in both cost and time, such as combined health worker training, reprinting new vaccination cards or monitoring forms, etc. The option to undertake a joint introduction should be discussed with the Minister of Health, the National Immunisation Technical Advisory Group (NITAG), and local and regional immunisation staff as soon as possible to plan accordingly.iv 9. If a country introduces two vaccines at once, will the country receive one or two Vaccine Introduction Grants (VIGs) from GAVI? Countries will receive a Vaccine Introduction Grant (VIG) for each eligible vaccine introduction. The VIG is a one-time cash grant to support a share of the additional costs related to the new vaccine introduction, with any remainder necessary, being funded by the government or partners. There is no reduction of the VIG in the case of joint introductions. Countries should provide details of how any potential cost savings will be utilised to support additional vaccine introduction activities. 4 10. Can a country apply to GAVI for support for IPV campaigns? GAVI support is available for one dose of IPV provided through the routine immunisation programme. GAVI support for IPV is not available for campaigns (including catch-up campaigns). However, support could be provided for a phased national rollout for countries that are interested in introducing IPV in their routine immunisation system in parts of the country before expanding their introduction to cover the rest of the country.
Load more

Recommended publications
  • The Hexavalent Dtap/IPV/Hib/Hepb Combination Vaccine: Information for Healthcare Practitioners About the Neonatal Selective
    The hexavalent DTaP/IPV/Hib/HepB combination vaccine Information for healthcare practitioners about the neonatal selective immunisation programme for babies at risk of hepatitis B The Hexavalent DTaP/IPV/Hib/HepB combination vaccine: Information for Healthcare Practitioners (selective programme) About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, research, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland For queries relating to this document, please contact: [email protected] © Crown copyright 2020 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. First published November 2017 This updated version published February
    [Show full text]
  • For Schools and Parents: K-12 Immunization Requirements
    FOR SCHOOLS AND PARENTS: K-12 IMMUNIZATION REQUIREMENTS NJ Department of Health (NJDOH) Vaccine Preventable Disease Program Summary of NJ School Immunization Requirements Listed in the chart below are the minimum required number of doses your child must have to attend a NJ school.* This is strictly a summary document. Exceptions to these requirements (i.e. provisional admission, grace periods, and exemptions) are specified in the Immunization of Pupils in School rules, New Jersey Administrative Code (N.J.A.C. 8:57-4). Please reference the administrative rules for more details https://www.nj.gov/health/cd/imm_requirements/acode/. Additional vaccines are recommended by Advisory Committee on Immunization Practices (ACIP) for optimal protection. For the complete ACIP Recommended Immunization Schedule, please visit http://www.cdc.gov/vaccines/schedules/index.html. Minimum Number of Doses for Each Vaccine Grade/level child DTaP Polio MMR Varicella Hepatitis Meningococcal Tdap enters school: Diphtheria, Tetanus, acellular Pertussis Inactivated (Measles, (Chickenpox) B (Tetanus, Polio Vaccine Mumps, diphtheria, (IPV) Rubella) acellular pertussis) § | Kindergarten – A total of 4 doses with one of these doses A total of 3 2 doses 1 dose 3 doses None None 1st grade on or after the 4th birthday doses with one OR any 5 doses† of these doses given on or after the 4th birthday ‡ OR any 4 doses nd th † 2 – 5 grade 3 doses 3 doses 2 doses 1 dose 3 doses None See footnote NOTE: Children 7 years of age and older, who have not been previously vaccinated with the primary DTaP series, should receive 3 doses of Td.
    [Show full text]
  • Download File (Pdf)
    2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION 2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION Foreword by Mo Ibrahim Notwithstanding these measures, on current projections Founder and Chair of the Mo Ibrahim Africa might not be adequately covered before 2023. Foundation (MIF) Vaccinating Africa is an urgent matter of global security and all the generous commitments made by Africa’s partners must now be delivered. Looking ahead - and inevitably there will be future pandemics - Africa needs to significantly enhance its Over a year ago, the emergence and the spread of COVID-19 homegrown vaccine manufacturing capacity. shook the world and changed life as we knew it. Planes were Africa’s progress towards its development agendas was off grounded, borders were closed, cities were shut down and course even before COVID-19 hit and recent events have people were told to stay at home. Other regions were hit created new setbacks for human development. With very earlier and harder, but Africa has not been spared from the limited access to remote learning, Africa’s youth missed out pandemic and its impact. on seven months of schooling. Women and girls especially The 2021 Ibrahim Forum Report provides a comprehensive are facing increased vulnerabilities, including rising gender- analysis of this impact from the perspectives of health, based violence. society, politics, and economics. Informed by the latest data, The strong economic and social impacts of the pandemic it sets out the challenges exposed by the pandemic and the are likely to create new triggers for instability and insecurity.
    [Show full text]
  • UNICEF Pentavalent-Hexa 2021+ Pre-Tender Industry Consultation
    UNICEF Pentavalent-Hexa 2021+ Pre-Tender Industry Consultation 19th SEPTEMBER 2019 1 Presentation Outline 1. Context ▪ Gavi Board decision ▪ Hexa strategic alignment ▪ Value Based Assessment 2. Demand scenarios and assumptions 3. Pentavalent Tender: ▪ Objectives ▪ Scope ▪ Duration ▪ Modality 4. Summary of feedback and response to questionnaire 5. Timelines 1. CONTEXT Gavi Board decision Hexa strategic alignment Value Based Assessment 3 Gavi Board November 2018 – Decisions IPV Post-2020 DTP booster VIS 2018 VIS 2018 + Hexavalent as immunisation option • Approved support for D, T & P vaccines (Td, DTwP, pentavalent) to be used as booster doses beginning in 2021 • Approved support for inactivated poliovirus vaccine (IPV), with country financing arrangements subject to alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting* • Approved in principle support of wP-Hexavalent vaccine, subject to a vaccine being licenced, recommended for use by WHO, WHO pre-qualified and that market attributes support the successful implementation of Hexavalent The development of capacity for standalone IPV remains the main priority for Gavi Alliance as part of the effort to eradicate polio All Gavi Board decisions are “subject to the availability of funding for the 2021-2025 period and alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting.” *Gavi's Board approved IPV co-financing arrangements post-2020 in its June 2019 session 4 Conditions to open a funding window for Hexavalent Condition 1: Hexavalent vaccines that are candidates for Gavi support should achieve IPV immunogenicity targets as per WHO’s SAGE recommendations. Condition 2: Hexavalent vaccines are priced in line with value-based principles.
    [Show full text]
  • Case Studies Controversies in Vaccination
    European Review, Vol. 21, No. S1, S56–S61 r 2013 Academia Europæa. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution license ,http://creativecommons.org/licenses/by/3.0/.. doi:10.1017/S1062798713000227 Session 3 – Case Studies Controversies in Vaccination ROMAN PRYMULA University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. E-mail: [email protected] Infectious diseases still jeopardize human health and even lives. In spite of the variety of advanced treatment methods, prevention is considered to be the most effective way to fight infections, and vaccination, no doubt, is one of the most effective preventive measures in the history of mankind. The vaccine controversy is based on a dispute over morality, ethics, effectiveness, and/or safety. There is no 100% safe or effective vaccine; however, benefits clearly overweigh risks. Ironically, as the numbers of cases of vaccine- preventable infectious diseases are falling, the controversies relating to vaccine safety are growing. Vaccines are generally victims of their own success. Controversies can afflict the positive acceptance of immunization, decrease the coverage and uptake and finally threaten the health of children and adults. The advent of vaccination has proven to be one of the most effective preventive measures in the history of medicine. Vaccines play a significant role in the prevention of debili- tating and, in many cases, life-threatening infectious diseases. Vaccines also provide important benefits in terms of reducing or avoiding costs associated with illness, both direct and indirect. In spite of the absence of any kind of ideal global healthcare system and lack of resources, the World Health Organisation (WHO) and the United Nations Children’s Fund (UNICEF) were able, in 1974, to establish a major global project called the Expanded Programme on Immunization (EPI).
    [Show full text]
  • Polio Vaccine May Be Given at the Same Time As Other Paralysis (Can’T Move Arm Or Leg)
    POLIO VVPOLIO AAACCINECCINECCINE (_________ W H A T Y O U N E E D T O K N O W ) (_I111 ________What is polio? ) (_I ________Who should get polio ) 333 vaccine and when? Polio is a disease caused by a virus. It enters a child’s (or adult’s) body through the mouth. Sometimes it does IPV is a shot, given in the leg or arm, depending on age. not cause serious illness. But sometimes it causes Polio vaccine may be given at the same time as other paralysis (can’t move arm or leg). It can kill people who vaccines. get it, usually by paralyzing the muscles that help them Children breathe. Most people should get polio vaccine when they are Polio used to be very common in the United States. It children. Children get 4 doses of IPV, at these ages: paralyzed and killed thousands of people a year before we 333 A dose at 2 months 333 A dose at 6-18 months had a vaccine for it. 333 A dose at 4 months 333 A booster dose at 4-6 years 222 Why get vaccinated? ) Adults c I Most adults do not need polio vaccine because they were Inactivated Polio Vaccine (IPV) can prevent polio. already vaccinated as children. But three groups of adults are at higher risk and should consider polio vaccination: History: A 1916 polio epidemic in the United States killed (1) people traveling to areas of the world where polio is 6,000 people and paralyzed 27,000 more. In the early common, 1950’s there were more than 20,000 cases of polio each (2) laboratory workers who might handle polio virus, and year.
    [Show full text]
  • Immunogenicity and Safety of a Fully Liquid Dtap-IPV-Hep B-PRP-T
    ccines & a V f V a o c l c i a n n a Lanata et al., J Vaccines Vaccin 2012, 3:1 r t u i o o n J Journal of Vaccines & Vaccination DOI: 10.4172/2157-7560.1000128 ISSN: 2157-7560 Research Article Open Access Immunogenicity and Safety of a Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine at 2-4-6 Months of Age in Peru Claudio Lanata1, Betzana Zambrano2, Lucie Ecker1, Isabel Amemiya1, Ana Gil1 and Eduardo Santos Lima3* 1Instituto de Investigación Nutricional, Lima, Peru 2Sanofi Pasteur, Montevideo, Uruguay 3Clinical Development, Sanofi Pasteur, Lyon, France Abstract Objectives: To assess the immunogenicity and safety of a new candidate, fully liquid, hexavalent DTaP-IPV- Hep B-PRP-T vaccine (Hexaxim™, an AcXim family vaccine) compared to a licensed hexavalent DTaP-IPV-Hep B// PRP-T vaccine (Infanrix hexa®) in Peru. Methods: Infants born to HBsAg seronegative mothers and who had not received a hepatitis B vaccine prior to entry into the study were randomized to receive either Hexaxim™ (Group 1) or Infanrix hexa® (Group 2) at 2, 4, 6 months of age. Seroprotection (SP) rate for hepatitis B (anti-HBs antibody concentration ≥10 mIU/mL) was analysed for non-inferiority (Group 1 minus Group 2) 1 month post-primary series. Anti-diphtheria and anti-polyrosil ribitol phosphate (PRP) antibody responses were analysed descriptively. Safety was analysed from parental reports. Results: Seroprotection rate for anti-HBs antibody titers ≥10 mIU/mL was high in both groups (≥99.2%) and non-inferiority was demonstrated (lower bound of the 95% CI for the difference was -4.17, above the pre-defined delta [-10%]).
    [Show full text]
  • Swine Flu and Polio Vaccines: Some Parallels and Some Differences
    Swine Fluand Polio Vaccines: Some Parallelsand Some Differences Howard B. Baumel College of Staten Island of the City Universityof New York Staten Island 10301 The swine flu vaccinationprogram vaccine could be successfullydevel- facturedby a single pharmaceutical generated debate in scientific and oped. company.The cause of this outbreak medical circlesthat extended to the Salkrelied heavily on his previous was never clearly established. Be- Downloaded from http://online.ucpress.edu/abt/article-pdf/39/9/550/36038/4446085.pdf by guest on 29 September 2021 general public.The controversythat experience as he attemptedto pro- cause bottles of tissue culture fluid centered on the vaccine's effective- duce a killedvirus polio vaccine.He containingthe virushad been stored ness and safety was reminiscentof used formalinto kill the virus and priorto being treated with formalin, the problemsthat accompaniedthe isolated one strain for each of the it was possiblethat bits of tissue had development of the polio vaccine three knowntypes of polio virus.To settled to the bottom covering the years ago. A review of that earlier determineif any live virusremained viruses and protecting them from scientific achievement can provide after the exposure to formalin,the the formalin.To prevent this, the insightsinto the swineflu dilemma. treated virus was injected into the tissue culture fluid was filtered to By the mid-1930's,only threeviral brain of a monkey. If the monkey remove the debris before exposure diseases,smallpox, rabies, and yellow contracted polio, it was concluded to formalin. fever, had yielded to vaccines. In that live viruswas present.To deter- HeraldCox and HilaryKoprowski each of these cases, the vaccine mine if the treated virus was effec- (1955, 1956) had developed an consisted of a live virus.
    [Show full text]
  • Polio Fact Sheet
    Polio Fact Sheet 1. What is Polio? - Polio is a disease caused by a virus that lives in the human throat and intestinal tract. It is spread by exposure to infected human stool: e.g. from poor sanitation practices. The 1952 Polio epidemic was the worst outbreak in the nation's history. Of nearly 58,000 cases reported that year, 3,145 people died and 21,269 were left with mild to disabling paralysis, with most of the victims being children. The "public reaction was to a plague", said historian William O'Neill. "Citizens of urban areas were to be terrified every summer when this frightful visitor returned.” A Polio vaccine first became available in 1955. 2. What are the symptoms of Polio? - Up to 95 % of people infected with Polio virus are not aware they are infected, but can still transmit it to others. While some develop just a fever, sore throat, upset stomach, and/or flu-like symptoms and have no paralysis or other serious symptoms, others get a stiffness of the back or legs, and experience increased sensitivity. However, a few develop life-threatening paralysis of muscles. The risk of developing serious symptoms increases with the age of the ill person. 3. Is Polio still a disease seen in the United States? - The last naturally occurring cases of Polio in the United States were in 1979, when an outbreak occurred among the Amish in several states including Pennsylvania. 4. What kinds of Polio vaccines are used in the United States? - There is now only one kind of Polio vaccine used in the United States: the Inactivated Polio vaccine (IPV) is given as an injection (shot).
    [Show full text]
  • 2021-22 School Year New York State Immunization Requirements for School Entrance/Attendance1
    2021-22 School Year New York State Immunization Requirements for School Entrance/Attendance1 NOTES: Children in a prekindergarten setting should be age-appropriately immunized. The number of doses depends on the schedule recommended by the Advisory Committee on Immunization Practices (ACIP). Intervals between doses of vaccine should be in accordance with the ACIP-recommended immunization schedule for persons 0 through 18 years of age. Doses received before the minimum age or intervals are not valid and do not count toward the number of doses listed below. See footnotes for specific information foreach vaccine. Children who are enrolling in grade-less classes should meet the immunization requirements of the grades for which they are age equivalent. Dose requirements MUST be read with the footnotes of this schedule Prekindergarten Kindergarten and Grades Grades Grade Vaccines (Day Care, 1, 2, 3, 4 and 5 6, 7, 8, 9, 10 12 Head Start, and 11 Nursery or Pre-k) Diphtheria and Tetanus 5 doses toxoid-containing vaccine or 4 doses and Pertussis vaccine 4 doses if the 4th dose was received 3 doses (DTaP/DTP/Tdap/Td)2 at 4 years or older or 3 doses if 7 years or older and the series was started at 1 year or older Tetanus and Diphtheria toxoid-containing vaccine Not applicable 1 dose and Pertussis vaccine adolescent booster (Tdap)3 Polio vaccine (IPV/OPV)4 4 doses 3 doses or 3 doses if the 3rd dose was received at 4 years or older Measles, Mumps and 1 dose 2 doses Rubella vaccine (MMR)5 Hepatitis B vaccine6 3 doses 3 doses or 2 doses of adult hepatitis B vaccine (Recombivax) for children who received the doses at least 4 months apart between the ages of 11 through 15 years Varicella (Chickenpox) 1 dose 2 doses vaccine7 Meningococcal conjugate Grades 2 doses vaccine (MenACWY)8 7, 8, 9, 10 or 1 dose Not applicable and 11: if the dose 1 dose was received at 16 years or older Haemophilus influenzae type b conjugate vaccine 1 to 4 doses Not applicable (Hib)9 Pneumococcal Conjugate 1 to 4 doses Not applicable vaccine (PCV)10 Department of Health 1.
    [Show full text]
  • Vaccinations for Preteens and Teens, Age 11-19 Years
    Vaccinations for Preteens and Teens, Age 11–19 Years Getting immunized is a lifelong, life-protecting job. Make sure you and your healthcare provider keep your immunizations up to date. Check to be sure you’ve had all the vaccinations you need. Vaccine Do you need it? Chickenpox Yes! If you haven’t been vaccinated and haven’t had chickenpox, you need 2 doses of this vaccine. (varicella; Var) Anybody who was vaccinated with only 1 dose should get a second dose. Hepatitis A Yes! If you haven’t been vaccinated, you need 2 doses of this vaccine. Anybody who was vaccinated (HepA) with only 1 dose should get a second dose at least 6–18 months later. Hepatitis B Yes! This vaccine is recommended for all people age 0–18 years. You need a hepatitis B vaccine series (HepB) if you have not already received it. Haemophilus influ- Maybe. If you haven’t been vaccinated against Hib and have a high-risk condition (such as a non- enzae type b (Hib) functioning spleen), you need this vaccine. Human Yes! All preteens need 2 doses of HPV vaccine at age 11 or 12. Older teens who haven't been vacci- papillomavirus nated will need 2 or 3 doses. This vaccine protects against HPV, a common cause of genital warts and (HPV) several types of cancer, including cervical cancer and cancer of the anus, penis, and throat. Influenza Yes! Everyone age 6 months and older needs annual influenza vaccination every fall or winter and (Flu) for the rest of their lives.
    [Show full text]
  • (Nitags) and WHO Immunisation-Related Advisory Committees
    Summary of recent issues considered by four national immunisation technical advisory groups (NITAGs) and WHO immunisation-related advisory committees Prepared by the National Centre for Immunisation Research & Surveillance (NCIRS) Period of review: 16/05/2019 to 13/09/2019 Contents 1 Advisory Committee on Immunization Practices (ACIP), USA .......................................................... 3 1.1 ACIP meeting: 26-27 June 2019 ....................................................................................................... 3 1.2 Newly published or updated recommendations ............................................................................... 20 1.2.1 Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunisation Practices.......................................................................................................................... 20 1.2.2 Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practice ..................................................................................................... 20 1.2.3 Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season ............ 21 1.3 New or updated recommendations – not yet published ................................................................... 21 2 Immunisation Advisory Centre (IMAC), New Zealand ....................................................................
    [Show full text]